Clinical features of overweight in acute-phase hospitalised major depressive disorder with comorbid anxiety: a cross-sectional study.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 39987012.
- Also identified by DOI 10.1136/bmjopen-2024-087640 and PMC identifier 11848675.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study aimed to investigate the incidence of overweight in patients with major depressive disorder (MDD) comorbid anxiety during the acute phase and to explore associated factors. Cross-sectional study. Wuhan Mental Health Center, China, from July 2017 to August 2022. 737 hospitalised patients diagnosed with MDD in the acute phase with comorbid anxiety symptoms. Incidence and clinical correlations of overweight (body mass index (BMI) ≥ 24). Among the study population, 55.63% were classified as overweight. Binary logistic regression analysis revealed that being married (B=0.28, p value=0.018, OR=1.10), thyroid-stimulating hormone (TSH) levels (B=0.10, p value=0.001, OR=1.10) and low-density lipoprotein cholesterol (LDL-C) levels (B=1.61, p value=0.045, OR=1.18) were significant positive predictors of overweight. Additionally, multiple linear regression indicated that TSH levels (B=0.16, t=3.17, p value=0.002) were positively associated with higher BMI values. Over half of the hospitalised MDD patients with comorbid anxiety are overweight. Thyroid function emerges as a crucial clinical factor for overweight in this population. Targeted interventions focusing on thyroid function may be a promising approach for managing overweight in these patients.
Medical subject headings
- Major Depressive Disorder
- Overweight
- Anxiety